Decline in renal concentration ability in lithium treated patients

Decline in renal concentration ability in lithium treated patients - Nephrogenic diabetes insipidus (NDI) in lithium treated patients

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON50138

Enrollment

Registered

2022-01-17

Start date

2022-07-11

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lithium-induced nephrogenic diabetes insipidus

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: o included in the previous study o men and women o age >= 18 years

Exclusion criteria

Exclusion criteria: general contra-indications for participation in a trial: -inability to give informed consent -pregnancy -unstable psychiatric condition alternative causes of (nephrogenic) diabetes insipidus: - hypokalemia (plasma potassium 2.80 mmol/l) - hyperglycemia (plasma glucose > 10.0 mmol/l) - history of amyloidosis, Sjögren*s syndrome or Sickle cell anemia - previous treatment with ifosfamide - established primary polydipsia or central diabetes insipidus contra-indications for dDAVP administration: - inability to comply with water restriction - renal insufficiency (GFR

Design outcomes

Primary

Measure	Time frame
Maximal urinary osmolality after intranasal administration of dDAVP.	—

Secondary

Measure	Time frame
- To determine the correlation between changes in kidney function and renal concentration ability - To determine the number of patients with chronic kidney disease - To determine the relation of the dDAVP test results with complaints (micturition history) and clinical parameters (duration of lithium therapy, plasma lithium concentration, baseline plasma creatinine, sodium and potassium concentration and baseline urinary osmolality) of lithium treated patients. - To determine the correlation between renal concentration ability and clinical parameters (duration of lithium therapy, plasma lithium concentration, baseline plasma creatinine, sodium and potassium concentration and baseline urinary osmolality)	—

Measure

Time frame

- To determine the correlation between changes in kidney function and renal concentration ability - To determine the number of patients with chronic kidney disease - To determine the relation of the dDAVP test results with complaints (micturition history) and clinical parameters (duration of lithium therapy, plasma lithium concentration, baseline plasma creatinine, sodium and potassium concentration and baseline urinary osmolality) of lithium treated patients. - To determine the correlation between renal concentration ability and clinical parameters (duration of lithium therapy, plasma lithium concentration, baseline plasma creatinine, sodium and potassium concentration and baseline urinary osmolality)

—

Countries

Netherlands

Outcome results